-
Mashup Score: 41
Objectives. This study was performed to the efficacy, safety and clinical consequences of abrupt cessation of quinapril therapy in a placebo-controlle…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 13Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction - 2 year(s) ago
This post hoc analysis of a randomized clinical trial evaluates the safety and efficacy of empagliflozin in patients with heart failure and preserved ejection fraction who are taking diuretics.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
In this Post Hoc Analysis of the #EMPEROR-Preserved Trial, #empagliflozin use was associated with improvement in HHF or CV ☠️, first HHF, total HHF, #eGFR slope, and KCCQ scores in patients with #HFpEF, regardless of background diuretics use or dose https://t.co/uZMrxBJpqf… https://t.co/DkvK0qajyw https://t.co/1zWV283LIs
-
-
Mashup Score: 10Effect of Empagliflozin on Circulating Proteomics in Heart Failure: Mechanistic Insights from the EMPEROR Program - 2 year(s) ago
AbstractBackground. Sodium glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse patient populations, but their mechanism of ac
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Effect of Empagliflozin on Circulating Proteomics in Heart Failure: Mechanistic Insights from the EMPEROR Program! https://t.co/3T9j2WE4qB #HF #proteomics #SGLT2 #EMPEROR #cardiotwitter @escardio @ESC_Journals
-
-
Mashup Score: 18ACC Cardiology Hour From ESC Congress 2022 - 2 year(s) ago
JACC Editor-in-Chief Valentin Fuster, MD, PhD, MACC, is joined by Michael A. Borger, MD, PhD, FACC; Bonnie Ky, MD, MSCE, FACC; Jonathan P. Piccini, MD, MHS, …
Source: YouTubeCategories: Cardiologists, Latest HeadlinesTweet-
ACC Cardiology Hour From #ESCCongress 2022 Highlights/key takeaways #PANTHER (3:00) #INVICTUS (14:17) #REVIVED (23:48) #DELIVER & #EMPEROR-Preserved Meta-analysis (34:55) #DELIVER (43:07) #SECURE (48:40) #DANCAVAS (1:00:20) 👇🏻 https://t.co/25bfxGJgxF @JACCJournals @escardio https://t.co/wRTAu8he9j
-
-
Mashup Score: 17Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved: - 3 year(s) ago
Abstract Background N-terminal pro–B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) are associated with disease severity and outcomes among patients with hea…
Source: JACC: Heart FailureCategories: Cardiologists, Latest HeadlinesTweet-
Elevations of baseline levels of both #NTproBNP and #hscTnT were associated with significantly ⬆️ risk of both cardiac and renal outcomes in #EMPEROR-Preserved, underscoring their prognostic value in #HFpEF populations https://t.co/gN43446YZ6 #HeartFailure #JACCHF @JJheart_doc https://t.co/q4OBQz5IoD
-
-
Mashup Score: 26Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure - 3 year(s) ago
This editorial refers to ‘Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled’, by J.P. Ferreira et al., https://doi.org/10.1093
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure: read more in EHJ! https://t.co/zaEfcoNBWp #SGLT2 #hyperkalaemia #HF #EMPEROR #cardiotwitter @escardio @ESC_Journals https://t.co/zlwaoF8ogQ
-
-
Mashup Score: 7
AbstractAims. Hyperkalaemia frequently leads to interruption and discontinuation of neurohormonal antagonists, which may worsen heart failure prognosis. Some st
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Empagliflozin and serum K+ in HF : an analysis from #EMPEROR-Pooled #Empagliflozin ⬇️ the incidence of hyperK+ , without significant increase in hypoK+, in patients with #HeartFailure across the full range of EF https://t.co/msp4UoEAIb @ESC_Journals @FaiezZANNAD @JavedButler1 https://t.co/sdTqWUOoWi
-
-
Mashup Score: 6All-Cause Mortality as an End Point for Heart Failure With Preserved Ejection Fraction: Underperformance or Overambitious? - 3 year(s) ago
EMPEROR-PRESERVED, which examined sodium-glucose co-transporter 2 inhibitor empagliflozin, is the first study among patients with heart failure with preserved ejection fraction (HFpEF) to meet its primary end point.1 This is a major development for patients with HFpEF and the broader scientific community; all previous studies in HFpEF have failed to meet their primary end point. This includes the…
Source: Journal of Cardiac FailureCategories: Cardiologists, Latest HeadlinesTweet-
All-Cause Mortality as an End Point for #HFpEF : Underperformance or Overambitious? Ongoing discussions about the #EMPEROR-PRESERVED study will re-emphasize the importance of patient-centered end points beyond all-cause ☠️ https://t.co/KyddiqfQLL @ParagGoyalMD @AndrewJSauer https://t.co/UAbd9FZuoJ
-
-
Mashup Score: 13
Abstract. In the year 2021, the universal definition and classification of heart failure (HF) was published that defines HF as a clinical syndrome with symptoms
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
The year in CV medicine 2021: heart failure and cardiomyopathies Summary of the universal definition and EF classification of HF; management of #HFrEF according to 2021 ESC guidelines for #HF and results of the #EMPEROR-preserved trial https://t.co/pwnbUOL3fj @escardio @BiykemB https://t.co/9YYa4Ql57S
-
-
Mashup Score: 1Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction - 3 year(s) ago
AbstractAims . No therapy has shown to reduce the risk of hospitalization for heart failure across the entire range of ejection fractions seen in clinical pract
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Published today in @escardio #EHJ by @JavedButler1. Empagliflozin effects in HF across LVEF as a continuous function in #EMPEROR Spline for primary endpoint (CVd+ first HFH) appears convincing for benefits across the board without significant interaction https://t.co/rHvTjLRbiJ https://t.co/pl7LZYMxoh https://t.co/OXI9itovBA
-
📂 https://t.co/OkyC6Cmd4S
-
Withdrawal of #GDMT in HF consistently ➡️adverse clinical course⚠️ #ACEi in HFrEF (#QuinaprilHeartStudy) https://t.co/9AsSNhBxAv #SGLT2i in HF (#EMPEROR) https://t.co/Z6FPyhABjs #MRA in HFmrEF/HFpEF (tested in #FINEARTS) #GDMT in HFimpEF DCM (#TREDHF) https://t.co/oKGUIWqjXB https://t.co/JJz252EpAL https://t.co/39HPhyZHjw